HK1016174A1 - Nitrogenous heterocyclic compounds - Google Patents

Nitrogenous heterocyclic compounds

Info

Publication number: HK1016174A1
Authority: HK; Hong Kong
Prior art keywords: substituted; atom; alkyl group; nitrogen atom; unsubstituted
Prior art date: 1996-10-01

Application number

HK99101245.3A

Other languages

English (en)

Inventor

Kenji Matsuno

Michio Ichimura

Yuji Nomoto

Shigeki Fujiwara

Shinichi Ide

Eiji Tsukuda

Junko Irie

Shoji Oda

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-01

Filing date

1999-03-24

Publication date

1999-10-29

1999-03-24 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

1999-10-29 Publication of HK1016174A1 publication Critical patent/HK1016174A1/xx

Links

-1 Nitrogenous heterocyclic compounds Chemical class 0.000 title abstract 4
125000000217 alkyl group Chemical group 0.000 abstract 5
229910052757 nitrogen Inorganic materials 0.000 abstract 4
125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
125000002723 alicyclic group Chemical group 0.000 abstract 2
125000005843 halogen group Chemical group 0.000 abstract 2
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
108091008606 PDGF receptors Proteins 0.000 abstract 1
102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 abstract 1
230000002159 abnormal effect Effects 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
206010061989 glomerulosclerosis Diseases 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000004430 oxygen atom Chemical group O* 0.000 abstract 1
230000026731 phosphorylation Effects 0.000 abstract 1
238000006366 phosphorylation reaction Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
125000004434 sulfur atom Chemical group 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyridine Compounds (AREA)

HK99101245.3A 1996-10-01 1999-03-24 Nitrogenous heterocyclic compounds HK1016174A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP26074396		1996-10-01
PCT/JP1997/003510 WO1998014431A1 (fr)	1996-10-01	1997-10-01	Composes azotes heterocycliques

Publications (1)

Publication Number	Publication Date
HK1016174A1 true HK1016174A1 (en)	1999-10-29

Family

ID=17352137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK99101245.3A HK1016174A1 (en)	1996-10-01	1999-03-24	Nitrogenous heterocyclic compounds

Country Status (14)

Country	Link
US (4)	US6169088B1 (de)
EP (1)	EP0882717B1 (de)
JP (1)	JP4073961B2 (de)
KR (1)	KR100622323B1 (de)
CN (1)	CN1169795C (de)
AT (1)	ATE480521T1 (de)
AU (1)	AU719392B2 (de)
CA (1)	CA2239227C (de)
DE (1)	DE69739986D1 (de)
DK (1)	DK0882717T3 (de)
ES (1)	ES2351684T3 (de)
HK (1)	HK1016174A1 (de)
NZ (1)	NZ330571A (de)
WO (1)	WO1998014431A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ291386B6 (cs)	1996-02-13	2003-02-12	Zeneca Limited	Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
NZ334125A (en)	1996-09-25	2000-10-27	Zeneca Ltd	Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
CA2326324C (en) *	1998-03-31	2010-05-11	Kyowa Hakko Kogyo Co., Ltd.	Nitrogen-containing heterocyclic compound
US6184226B1 (en) *	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
DK1119567T3 (da)	1998-10-08	2005-07-25	Astrazeneca Ab	Quinazolinderivater
JP3270834B2 (ja)	1999-01-27	2002-04-02	ファイザー・プロダクツ・インク	抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en)	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
US6455734B1 (en)	2000-08-09	2002-09-24	Magnesium Diagnostics, Inc.	Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9919558D0 (en) *	1999-08-18	1999-10-20	Hoechst Schering Agrevo Gmbh	Fungicidal compounds
JP2001131151A (ja) *	1999-11-02	2001-05-15	Shionogi & Co Ltd	オレフィン誘導体の新規用途
CN101219145A (zh)	1999-11-05	2008-07-16	阿斯特拉曾尼卡有限公司	作为vegf抑制剂的喹唑啉衍生物
KR100774855B1 (ko) *	2000-04-27	2007-11-08	아스텔라스세이야쿠 가부시키가이샤	축합 헤테로아릴 유도체
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
CA2411101C (en)	2000-06-05	2018-01-16	Brigham And Women's Hospital, Inc.	A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
AU2001264376A1 (en) *	2000-06-15	2001-12-24	Chaconne Nsi Co., Ltd.	Urea derivative useful as an anti-cancer agent and process for preparing same
AU8066701A (en)	2000-07-20	2002-02-05	Neurogen Corp	Capsaicin receptor ligands
JP2004505966A (ja)	2000-08-09	2004-02-26	アストラゼネカ　アクチボラグ	シンノリン化合物
CN1315822C (zh)	2000-08-09	2007-05-16	阿斯特拉曾尼卡有限公司	具有vegf抑制活性的喹啉衍生物
US7329655B2 (en)	2000-08-18	2008-02-12	Millennium Pharmaceuticals, Inc.	Nitrogenous heterocyclic compounds
DK1309569T3 (da) *	2000-08-18	2011-01-24	Millennium Pharm Inc	N-aryl-{4-[7-(alkoxy)quinazolin-4-yl]piperazinyl}carboxamidderivater som PDGFRs-inhibitorer
EP1309567A2 (de) *	2000-08-18	2003-05-14	Millennium Pharmaceuticals, Inc.	Stickstoffhaltige heterozyklische verbindungen
KR100831116B1 (ko) *	2000-08-18	2008-05-20	밀레니엄 파머슈티컬스 인코퍼레이티드	키나아제 억제제로서의 퀴나졸린 유도체
AU2002217999A1 (en)	2000-11-01	2002-05-15	Cor Therapeutics, Inc.	Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US20040259881A1 (en) *	2001-02-02	2004-12-23	Anjali Pandey	Nitrogenous heterocyclic compounds
BR0207663A (pt) *	2001-02-27	2005-10-25	Univ Michigan	Uso de inibidores de egfr naturais para prevenir os efeitos colaterais devido à terapia com retinóides, sabões e outros estìmulos que ativam o receptor do fator de crescimento epidérmico
US6960580B2 (en)	2001-03-08	2005-11-01	Millennium Pharmaceuticals, Inc.	Nitrogenous heterocyclic substituted quinoline compounds
US6896949B1 (en)	2001-03-15	2005-05-24	Bookham (Us) Inc.	Wafer scale production of optical elements
MXPA03010565A (es) *	2001-05-21	2004-03-02	Hoffmann La Roche	Derivados de quinolina como ligandos para receptor del neuropeptido y.
US8124625B2 (en)	2001-09-14	2012-02-28	Shionogi & Co., Ltd.	Method of enhancing the expression of apolipoprotein AI using olefin derivatives
US6787558B2 (en)	2001-09-28	2004-09-07	Hoffmann-La Roche Inc.	Quinoline derivatives
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati
WO2003080586A1 (en) *	2002-03-21	2003-10-02	Abbott Laboratories	N-sulfonylurea apoptosis promoters
US7030115B2 (en)	2002-03-21	2006-04-18	Abbott Laboratories	N-sulfonylurea apoptosis promoters
CN1678586A (zh) *	2002-06-27	2005-10-05	舍林股份公司	取代的喹啉ccr5受体拮抗剂
CL2004000409A1 (es)	2003-03-03	2005-01-07	Vertex Pharma	Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7713983B2 (en)	2003-03-03	2010-05-11	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
ES2388138T3 (es)	2003-08-27	2012-10-09	Ophthotech Corporation	Terapia de combinación para tratamiento de trastornos neovasculares oculares
AU2004275842B2 (en)	2003-09-26	2010-09-02	Exelixis Inc.	c-MET modulators and methods of use
ATE437872T1 (de)	2003-10-14	2009-08-15	Univ Arizona	Proteinkinaseinhibitoren
US20090099165A1 (en)	2003-10-14	2009-04-16	Arizona Board Of Regents On Behalf Of The University Of Arizona	Protein Kinase Inhibitors
WO2005097137A2 (en) *	2004-03-31	2005-10-20	The Scripps Research Institute	Advanced quinazoline based protein kinase inhibitors
US7928107B2 (en)	2004-09-02	2011-04-19	Vertex Pharmaceuticals Incorporated	Quinazolines useful as modulators of ion channels
EP1802585A1 (de) *	2004-09-03	2007-07-04	Memory Pharmaceuticals Corporation	4-substituierte 4,6-dialkoxycinnolinderivate als phosphodiesterase-10-inhibitoren zur behandlung psychiatrischer oder neurologischer syndrome
GB0503056D0 (en) *	2005-02-14	2005-03-23	Smithkline Beecham Corp	Chemical compounds
CN101166730A (zh)	2005-03-01	2008-04-23	惠氏公司	噌啉化合物及其作为肝x受体调节剂的用途
ATE421510T1 (de) *	2005-03-28	2009-02-15	Bristol Myers Squibb Co	Kompetitive atp-kinasehemmer
JP2008539277A (ja) *	2005-04-28	2008-11-13	スーパージェン，インコーポレイテッド	プロテインキナーゼインヒビター
US7825244B2 (en)	2005-06-10	2010-11-02	Janssen Pharmaceutica Nv	Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en)	2005-06-10	2011-12-06	Janssen Pharmaceutica, N.V.	Alkylquinoline and alkylquinazoline kinase modulators
US20100179162A1 (en) *	2005-07-20	2010-07-15	Millennium Pharmaceuticals , Inc.	Crystal forms of 4-[6-methoxy-7(3-piperidin-1-yl-propoxy) quinazoline-4yl) piperazine-1-carboxylic acid (4-isopropoxyphenyl)-amide
AU2013211455B2 (en) *	2005-09-19	2017-12-07	Neuronascent, Inc.	Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration
WO2007098214A1 (en) *	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
CA2643963A1 (en) *	2006-02-21	2007-08-30	Amgen Inc.	Cinnoline derivatives as phosphodiesterase 10 inhibitors
MX2008010953A (es) *	2006-02-28	2008-09-08	Amgen Inc	Derivados de cinolina y quinoxalina como inhibidores de la fosfodiesterasa 10.
US20090099175A1 (en) *	2006-03-01	2009-04-16	Arrington Mark P	Phosphodiesterase 10 inhibitors
AU2007223801A1 (en) *	2006-03-08	2007-09-13	Amgen Inc.	Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
US8106071B2 (en) *	2007-02-21	2012-01-31	Biobud Co., Ltd.	Compositions for treating hyperproliferative vascular disorders and cancers
CA2682733A1 (en) *	2007-04-13	2008-10-23	Supergen, Inc.	Axl kinase inhibitors
CN102202737B (zh) *	2008-11-03	2014-03-26	伊莱利利公司	二取代的2,3-二氮杂萘hedgehog通路拮抗剂
WO2010059239A2 (en) *	2008-11-21	2010-05-27	Millennium Pharmaceuticals, Inc	Lactate salt of 4-(6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
KR20210151988A (ko)	2009-01-16	2021-12-14	엑셀리시스, 인코포레이티드	암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US20120189641A1 (en)	2009-02-25	2012-07-26	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20130029978A1 (en) *	2009-12-25	2013-01-31	Mochida Pharmaceutical Co., Ltd.	Novel aryl urea derivative
EP2702173A1 (de)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Verwendung von emt-gensignaturen bei der entdeckung von krebswirkstoffen, -diagnostika und -behandlungen
EP2734205B1 (de)	2011-07-21	2018-03-21	Tolero Pharmaceuticals, Inc.	Heterocyclische proteinkinase-hemmer
EP2771011A4 (de)	2011-10-24	2015-04-15	Glaxosmithkline Ip No 2 Ltd	Chemische verbindungen
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
JP6506694B2 (ja) *	2012-11-20	2019-04-24	メリアルインコーポレイテッド	駆虫性化合物及び組成物並びにこれらの使用方法
CN103601722B (zh) *	2013-09-13	2016-03-02	南京华威医药科技开发有限公司	新型抗肿瘤化合物
MA41169A (fr) *	2014-12-17	2017-10-24	Acraf	Composés antibactériens à large spectre d'activité
EP3433249B1 (de) *	2016-03-21	2022-11-09	Council Of Scientific & Industrial Research	Blockierung der toll-ähnlichen rezeptor-9-signalisierung mit niedermolekularen antagonisten
CN108191756B (zh) *	2017-12-12	2020-08-25	绍兴文理学院	一种喹啉衍生物及其制备方法和应用
AU2019247498A1 (en)	2018-04-05	2020-11-26	Sumitomo Pharma Oncology, Inc.	AXL kinase inhibitors and use of the same
CN113412262A (zh)	2019-02-12	2021-09-17	大日本住友制药肿瘤公司	包含杂环蛋白激酶抑制剂的制剂
CN114920704B (zh) *	2019-07-26	2023-11-03	暨南大学	一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
WO2021020902A1 (ko) *	2019-07-30	2021-02-04	주식회사 하임바이오	신규한 항암용 화합물, 및 이를 유효성분으로 포함하는 약학조성물
WO2023280317A1 (zh) *	2021-07-09	2023-01-12	南京明德新药研发有限公司	苄氨基三并环类化合物及其应用
CN115677702A (zh) *	2021-07-23	2023-02-03	武汉誉祥医药科技有限公司	三并环化合物及其药物组合物和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3723434A (en) *	1970-07-17	1973-03-27	Pfizer	Piperazino isoquinoline bronchodilators
JPS58172379A (ja) *	1982-04-02	1983-10-11	Showa Denko Kk	新規なキナゾリン誘導体
JPS60120872A (ja) *	1983-12-01	1985-06-28	Kyowa Hakko Kogyo Co Ltd	新規なヘテロ環状化合物及び強心剤
JPH02167277A (ja) *	1988-09-19	1990-06-27	Kyowa Hakko Kogyo Co Ltd	新規なジアジン化合物
WO1992020642A1 (en) *	1991-05-10	1992-11-26	Rhone-Poulenc Rorer International (Holdings) Inc.	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
JP3229693B2 (ja) *	1993-02-22	2001-11-19	協和醗酵工業株式会社	ピペラジン誘導体
CA2148082A1 (en) *	1993-09-03	1995-03-09	Daisuke Machii	Imidazoquinazoline derivatives
FR2722788B1 (fr) *	1994-07-20	1996-10-04	Pf Medicament	Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
US5701492A (en) *	1996-03-29	1997-12-23	Canon Kabushiki Kaisha	Fail-safe flashing of EPROM

1997
- 1997-10-01 ES ES97943133T patent/ES2351684T3/es not_active Expired - Lifetime
- 1997-10-01 CA CA002239227A patent/CA2239227C/en not_active Expired - Fee Related
- 1997-10-01 CN CNB971917418A patent/CN1169795C/zh not_active Expired - Fee Related
- 1997-10-01 JP JP51638098A patent/JP4073961B2/ja not_active Expired - Fee Related
- 1997-10-01 KR KR1019980704125A patent/KR100622323B1/ko not_active IP Right Cessation
- 1997-10-01 DK DK97943133.5T patent/DK0882717T3/da active
- 1997-10-01 AT AT97943133T patent/ATE480521T1/de active
- 1997-10-01 DE DE69739986T patent/DE69739986D1/de not_active Expired - Lifetime
- 1997-10-01 NZ NZ330571A patent/NZ330571A/xx not_active IP Right Cessation
- 1997-10-01 AU AU44708/97A patent/AU719392B2/en not_active Ceased
- 1997-10-01 EP EP97943133A patent/EP0882717B1/de not_active Expired - Lifetime
- 1997-10-01 WO PCT/JP1997/003510 patent/WO1998014431A1/ja active IP Right Grant
1998
- 1998-06-01 US US09/088,199 patent/US6169088B1/en not_active Expired - Lifetime
1999
- 1999-03-24 HK HK99101245.3A patent/HK1016174A1/xx not_active IP Right Cessation
2000
- 2000-01-12 US US09/481,544 patent/US6207667B1/en not_active Expired - Lifetime
- 2000-12-13 US US09/734,918 patent/US6472391B2/en not_active Expired - Lifetime
2002
- 2002-08-26 US US10/227,302 patent/US6750218B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR19990071843A (ko)	1999-09-27
AU719392B2 (en)	2000-05-11
KR100622323B1 (ko)	2006-11-30
US20030229077A1 (en)	2003-12-11
JP4073961B2 (ja)	2008-04-09
DK0882717T3 (da)	2010-12-13
DE69739986D1 (de)	2010-10-21
US6472391B2 (en)	2002-10-29
CN1208404A (zh)	1999-02-17
NZ330571A (en)	1999-10-28
US6169088B1 (en)	2001-01-02
EP0882717A4 (de)	2002-06-19
ATE480521T1 (de)	2010-09-15
EP0882717B1 (de)	2010-09-08
CA2239227C (en)	2007-10-30
AU4470897A (en)	1998-04-24
WO1998014431A1 (fr)	1998-04-09
EP0882717A1 (de)	1998-12-09
US6750218B2 (en)	2004-06-15
US20020068734A1 (en)	2002-06-06
CA2239227A1 (en)	1998-04-09
ES2351684T3 (es)	2011-02-09
CN1169795C (zh)	2004-10-06
US6207667B1 (en)	2001-03-27

Legal Events

Date

Code

Title

Description

2010-04-01

AM

Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE NAME OF APPLICANT FROM KYOWA HAKKO KOGYO KABUSHIKI KAISHA TO KYOWA HAKKO KOGYO CO., LTD.

Effective date: 20100329

2016-04-29

PC

Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151001

Publication	Publication Date	Title
HK1016174A1 (en)	1999-10-29	Nitrogenous heterocyclic compounds
EP1067123A4 (de)	2002-04-03	Stickstoffenthaltende heterocyclische verbindungen
HU9401221D0 (en)	1994-08-29	New heterocyclic compounds
ATE204873T1 (de)	2001-09-15	Naphthyridinderivate als angiotensin-ii- antagonist-inhibitoren
IL128994A0 (en)	2000-02-17	Quinoline derivatives inhibiting the effect of growth factors such as vegf
ES8802518A1 (es)	1988-07-01	Un procedimiento para preparar derivados de isoxazol y furano.
DE69428142D1 (de)	2001-10-11	Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
ATE186301T1 (de)	1999-11-15	An den positionen 2 und 9 substituierte 4h-pyrido-(1,2-a)pyrimidin-4-one
ATE147625T1 (de)	1997-02-15	Hydantoin- oder imidazolidintrionderivate zur vorbeugung oder behandlung von niereninsuffizienz
DK0609289T3 (da)	1996-11-25	Imidazolderivater og farmaceutiske præparater med indhold deraf
DE69416235T2 (de)	1999-09-30	Triazin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69814800D1 (de)	2003-06-26	Epoxysuccinamid-derivate oder ihre salze
DE3764077D1 (de)	1990-09-06	Zentralwirkende muskelrelaxante.
EP0316456A4 (de)	1990-05-14	Ester-substituierte thienotriazoldiazepin-verbindungen und deren verwendung als arzneimittel.
ATE169015T1 (de)	1998-08-15	Aminobenzoesäure derivate
EP0990645A4 (de)	2002-01-02	Neue sulfonamid-derivate
EP0299076A4 (en)	1991-01-09	5-hydroxyindole-3-carboxamide compound and medicinal use thereof
NZ505110A (en)	2003-01-31	Neuroprotective agents
NO174670C (no)	1994-06-15	Analogifremgangsmåte for fremstilling av terapeutisk aktive 1H-pyrido(4,3-b)indol-1-on-derivater
UA40569C2 (uk)	2001-08-15	Похідні метилпіперазиназепіну, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі
GEP19960472B (en)	1996-05-27	Method of producing derivative of quinoline or its pharmaceutically acceptable ester, or their salts
TH18165A (th)	1996-04-19	สารยับยั้งการเกิดคีโมแทกซิของอีโอซีโนฟีล